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THE EFFECT OF TERIPARATIDE ON BONE REMODELING IS 
NOT RELATED TO SERUM LEVELS OD OSTEOPROTEGERIN AND RANKL
S. Salvadori, G. Martini, S. Gonnelli, B. Franci, M.S. Campagna, A. Avanzati, L. Gennari, 
R. Valenti, C. Caffarelli, B. Lucani, R. Nuti
Internal Medicine, University of Siena, Siena, Italy 
In vitro studies indicate that parathyroid hormone (PTH) decrease osteoprotegerin (OPG) secretion by the
osteoblasts and increase RANKL production. Studies in healthy men have shown a negative correlation
between endogenus PTH and serum OPG; moreover a decrease of serum OPG with an increase of
serum RANKL have been reported by an interventional study where postmenopausal women with gluco-
corticoid osteoporosis were treated with intermittent injections of PTH. 
The aim of this study is to evaluate the behaviour of serum OPG and RANKL in women with established
postmenopausal osteoporosis treated for six months with teriparatide (20 µg/die).
We enroled 21 women (aged 71.5±7.8 years) with one or more vertebral fractures and a T-score at den-
sitometric examination of lumbar spine or proximal femur lower than –2.5. Patients on treatment were in-
cluded in the study after a three months wash-out period. As control group, we studied 15 age-matched
women. A blood sample was drawn from each patient at baseline and after two, four and six months from
the beginning of PTH administration. Bone turnover was evaluated by: specific bone alkaline phos-
phatase (BSAP), osteocalcin (BGP), and intact N-terminal propeptide of type I procollagen (PINP) as
markers of bone formation; C-telopeptides of Type-I collagen (CTX) as markers of bone resorption.
Serum OPG and RANKL were assessed using a sandwich enzyme immunoassay (Osteoprotegerin and
RANKL, Biomedica, Austria). Precision intra and interassay was lower than 10%. Basal values of bone
markers, serum OPG and RANKL in treated patients and control group did not differ significantly. No cor-
relations were found between bone markers and serum OPG and RANKL at baseline. Patients on PTH
treatment showed a significant increase in both formation and resorption markers. The increase of BGP
and PINP resulted statistically significant after two months, while the increase of CTX became significant
after four months. The highest values of all markers were found at sixth months. Serum OPG and RANKL
levels did not change significantly, though they showed a tendency to increase. OPG peaked at fourth
month, while the highest value of RANKL was found at sixth month. These data confirm that teriparatide
stimulates bone formation by activating osteoblast function which leads, later, to osteoclast activation.
Serum OPG and RANKL do not appear to be involved in parathyroid action on bone. 
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